Geron Corporation
149 Commonwealth Drive
Menlo Park
California
94025
United States
Tel: 650-473-7700
Fax: 650-473-7750
Website: http://www.geron.com/
Email: info@geron.com
469 articles about Geron Corporation
-
Geron Corporation Human Embryonic Stem Cell Program Awarded UK Grant Funding
5/6/2008
-
Geron Corporation Reports 2008 First Quarter Financial Results
4/30/2008
-
Geron Corporation Announces Conference Call to Discuss Financial Results for the 2008 First Quarter
4/29/2008
-
Geron Corporation Presentations at the American Association for Cancer Research 2008 Annual Meeting
4/16/2008
-
Geron Corporation Receives Milestone Payment From Exeter Life Sciences, Inc.
4/15/2008
-
Geron Corporation Release: U.S. Patent Office Upholds Two Additional Human Embryonic Stem Cell Patents in Reexamination Decisions
3/11/2008
-
FDA Places Geron Corporation's GRNOPC1 IND on Clinical Hold
3/5/2008
-
Geron Corporation Reports Fourth Quarter and Annual 2007 Financial Results and Highlights
2/28/2008
-
Geron Corporation Release: U.S. Patent Office Upholds Key Human Embryonic Stem Cell Patent
2/28/2008
-
Geron Corporation Ranked in Biotechnology Patent Scorecard Published in The Wall Street Journal
2/14/2008
-
Geron Corporation to Present at Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/8/2008
-
Geron Corporation's Second U.S. Patent for Production of Pancreatic Islets from Human Embryonic Stem Cells Strengthens Company's Intellectual Property Position
2/5/2008
-
Dr. Thomas Okarma Resumes Direct Leadership of Geron Corporation's Oncology Drug Development Activities
1/25/2008
-
Geron Corporation and Sienna Cancer Diagnostics Enter Into License Agreement for Cancer Diagnostics
1/24/2008
-
Geron Corporation Receives Milestone Payment from Merck & Co., Inc. Triggered by IND Filing for Telomerase Cancer Vaccine Candidate
12/12/2007
-
Geron Corporation Initiates Clinical Trial of Telomerase Inhibitor Drug in Patients with Multiple Myeloma
11/28/2007
-
Geron Corporation to Present at Lazard Capital Markets Healthcare Conference
11/27/2007
-
Geron Corporation: Recent Advances in Cellular Reprogramming
11/21/2007
-
Journal of Neuroimmunology Publishes Study Results Showing That Geron Corporation's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11/13/2007
-
Data Show Geron Corporation's Cell-Based Therapeutic for Spinal Cord Injury Survives and Exhibits Remyelination for at Least Nine Months Following Injection
11/7/2007